← Back to Screener
Exelixis Inc (EXEL)
Price$44.38
Favorite Metrics
Price vs S&P 500 (26W)10.61%
Price vs S&P 500 (4W)1.50%
Market Capitalization$11.50B
P/E Ratio (Annual)14.69x
All Metrics
P/CF (Annual)13.00x
Book Value / Share (Quarterly)$8.23
P/TBV (Annual)17.27x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)12.93%
Cash Flow / Share (Quarterly)$3.34
Price vs S&P 500 (YTD)-1.62%
Gross Margin (TTM)96.39%
Net Profit Margin (TTM)33.73%
EPS (TTM)$2.78
10-Day Avg Trading Volume2.20M
EPS Excl Extra (TTM)$2.78
Revenue Growth (5Y)10.09%
EPS (Annual)$2.78
ROI (Annual)36.21%
Gross Margin (Annual)96.39%
Net Profit Margin (5Y Avg)18.35%
Cash / Share (Quarterly)$4.03
P/E Basic Excl Extra (TTM)14.69x
Revenue Growth QoQ (YoY)10.79%
EPS Growth (5Y)31.10%
P/E Normalized (Annual)14.69x
ROA (Last FY)27.51%
Revenue Growth TTM (YoY)6.85%
EBITD / Share (TTM)$3.20
ROE (5Y Avg)16.66%
Operating Margin (TTM)37.59%
Cash Flow / Share (Annual)$3.34
P/B Ratio5.32x
P/B Ratio (Quarterly)5.44x
Net Income / Employee (Annual)$1
EV / Revenue (TTM)4.75x
Net Interest Coverage (TTM)42.74x
ROA (TTM)27.99%
EPS Growth QoQ (YoY)71.73%
EV / EBITDA (TTM)12.22x
EPS Incl Extra (Annual)$2.78
Current Ratio (Annual)3.56x
Quick Ratio (Quarterly)3.32x
3-Month Avg Trading Volume2.69M
52-Week Price Return23.89%
EV / Free Cash Flow (Annual)12.58x
P/E Incl Extra (TTM)14.69x
Revenue / Employee (TTM)$2
Tangible BV / Share (Quarterly)$0.69
P/S Ratio (Annual)4.96x
Asset Turnover (Annual)0.82x
52-Week High$49.62
Operating Margin (5Y Avg)19.97%
EPS Excl Extra (Annual)$2.78
CapEx CAGR (5Y)-33.37%
Tangible BV CAGR (5Y)-26.34%
26-Week Price Return14.60%
Quick Ratio (Annual)3.32x
13-Week Price Return0.50%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)3.56x
Enterprise Value$11,014.815
Revenue / Share Growth (5Y)13.08%
Asset Turnover (TTM)0.83x
Book Value / Share Growth (5Y)3.50%
Revenue / Employee (Annual)$2
Inventory Turnover (Annual)2.87x
Pretax Margin (Annual)40.57%
Cash / Share (Annual)$4.03
3-Month Return Std Dev29.62%
Gross Margin (5Y Avg)96.35%
Net Income / Employee (TTM)$1
EBITDA CAGR (5Y)24.59%
EBITDA Interim CAGR (5Y)55.08%
ROE (Last FY)36.21%
Net Interest Coverage (Annual)5.08x
EPS Basic Excl Extra (Annual)$2.78
P/FCF (TTM)13.13x
Receivables Turnover (TTM)7.90x
EV / Free Cash Flow (TTM)12.58x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$2.78
Receivables Turnover (Annual)8.09x
ROI (TTM)36.89%
P/S Ratio (TTM)4.96x
Pretax Margin (5Y Avg)23.03%
Revenue / Share (Annual)$8.23
Tangible BV / Share (Annual)$0.52
Forward P/E13.39x
Free OCF CAGR (5Y)21.08%
Price vs S&P 500 (52W)-5.94%
P/E Ratio (TTM)14.69x
EPS Growth TTM (YoY)39.67%
Year-to-Date Return1.03%
5-Day Price Return-2.49%
EPS Normalized (Annual)$2.78
ROA (5Y Avg)12.82%
Net Profit Margin (Annual)33.73%
Month-to-Date Return3.24%
Cash Flow / Share (TTM)$0.36
EBITD / Share (Annual)$3.20
EPS Growth (3Y)70.35%
Operating Margin (Annual)37.59%
LT Debt / Equity (Annual)5.07x
P/CF (TTM)13.00x
ROI (5Y Avg)16.66%
P/E Excl Extra (TTM)14.69x
LT Debt / Equity (Quarterly)2.55x
EPS Basic Excl Extra (TTM)$2.78
P/TBV (Quarterly)12.86x
P/B Ratio (Annual)5.44x
Inventory Turnover (TTM)3.19x
Pretax Margin (TTM)40.57%
Book Value / Share (Annual)$8.23
Price vs S&P 500 (13W)-0.19%
Net Margin Growth (5Y)15.94%
Beta0.39x
P/FCF (Annual)13.13x
Revenue / Share (TTM)$8.40
ROE (TTM)36.89%
52-Week Low$33.76
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.81
3.74
3.74
3.74
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
EXELExelixis Inc | 4.96x | 6.85% | 96.39% | 31.10% | $44.38 |
AMGNAmgen Inc | 5.13x | 9.95% | 73.30% | 2.93% | $349.39 |
GILDGilead Sciences Inc | 5.84x | 2.40% | 78.83% | 133.64% | $138.55 |
ARGXargenx SE American Depositary Shares | 12.46x | 89.56% | 150.91% | — | $828.35 |
BNTXBioNTech SE American Depositary Share | 8.75x | -11.81% | 84.21% | — | $102.12 |
BIIBBiogen Inc. Common Stock | 2.60x | 2.22% | 75.69% | -18.77% | $176.02 |
MRNAModerna, Inc. Common Stock | 11.02x | -39.93% | 70.32% | — | $54.68 |
NBIXNeurocrine Biosciences Inc | 4.49x | 21.45% | 98.18% | 2.31% | $128.41 |
TECHBio-Techne Corp. | 7.60x | 1.64% | 66.60% | -20.58% | $57.36 |
HALOHalozyme Therapeutics, Inc. | 5.74x | 37.55% | 83.62% | 22.89% | $66.64 |
KRYSKrystal Biotech, Inc. Common Stock | 20.17x | 33.95% | 94.08% | — | $264.06 |
About
Exelixis Inc is a biopharmaceutical company that discovers and commercializes oncology treatments. Its portfolio includes Cabometyx for renal cell and hepatocellular carcinoma, Cometriq for metastatic medullary thyroid cancer, and Cotellic (in partnership with Roche) for melanoma.